通化金马具备丰富现有管线的资金基础 积极开拓对外合作机会

Core Viewpoint - Tonghua Golden Horse is actively preparing for the commercialization of its innovative drug, Huopo Batyhyl Amino Acids Tablets, which is currently undergoing final review by the National Medical Products Administration (NMPA) [1][2] Group 1: Company Overview - Tonghua Golden Horse primarily engages in the research, production, and sales of pharmaceutical products, with business units including Shengtai Biological, Yongkang Pharmaceutical, and Yuanshou Biological [1] - The company's product range covers various therapeutic areas such as oncology, microbiology, cardiovascular, detoxification, digestive system, musculoskeletal system, gynecology, and neurology [1] Group 2: Drug Development Progress - The Huopo Batyhyl Amino Acids Tablets, a national-level new drug with independent intellectual property rights, has completed all necessary clinical trials and is awaiting final review by the Center for Drug Evaluation (CDE) [2] - The company has submitted all required technical documents and completed expert review meetings in clinical, statistical, and pharmaceutical aspects as part of the new drug application process [2] Group 3: Commercialization Strategy - Tonghua Golden Horse has established a professional team and innovative marketing model to ensure control over the sales of the new drug, balancing profit margins with patient accessibility [2] - The existing production system is prepared to meet the demand for Alzheimer's disease treatment, ensuring rapid market entry post-approval [2] - The company is focusing on expanding its pipeline in the field of neurological diseases, aiming to create a robust research and development structure [2][3]